NCT00401375View on ClinicalTrials.gov

Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI)

PHASE3CompletedINTERVENTIONAL

Enrollment

524

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions

Post-Operative Ileus (POI)

Interventions

DRUG

Methylnaltrexone

Methylnaltrexone will be administered as per the dose and schedule specified in the respective arms.

DRUG

Placebo

Placebo matching to methylnaltrexone will be administered as per the schedule specified in the respective arm.

Trial Locations (1)

10591

Progenics Pharmaceuticals, Tarrytown

All Listed Sponsors

collaborator

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

lead

Bausch Health Americas, Inc.

INDUSTRY

NCT00401375 - Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI) | Biotech Hunter | Biotech Hunter